Trial · NCT00975130
Adverse events612
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 612
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 0 | 3,357 | 0 |
| other | Nasopharyngitis | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 13 | 245 | 15 |
| other | Nasopharyngitis | Infections and infestations | SC-GLM50 | 18 | 255 | 19 |
| other | Upper respiratory tract infection | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 0 | 3,357 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 15 | 245 | 17 |
| other | Upper respiratory tract infection | Infections and infestations | SC-GLM50 | 6 | 255 | 9 |
| serious | Pneumonia | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 9 | 3,357 | 10 |
| serious | Pneumonia | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 2 | 245 | 2 |
| serious | Pneumonia | Infections and infestations | SC-GLM50 | 1 | 255 | 1 |
| serious | Arthritis bacterial | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 5 | 3,357 | 5 |
| serious | Arthritis bacterial | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 0 | 245 | 0 |
| serious | Arthritis bacterial | Infections and infestations | SC-GLM50 | 0 | 255 | 0 |
| serious | Sepsis | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 5 | 3,357 | 5 |
| serious | Sepsis | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 1 | 245 | 1 |
| serious | Sepsis | Infections and infestations | SC-GLM50 | 0 | 255 | 0 |
| serious | Tuberculosis | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 4 | 3,357 | 5 |
| serious | Tuberculosis | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 0 | 245 | 0 |
| serious | Tuberculosis | Infections and infestations | SC-GLM50 | 0 | 255 | 0 |
| serious | Respiratory tract infection | Infections and infestations | Golimumab 50 mg Subcutaneous (GLM50-SC) | 3 | 3,357 | 3 |
| serious | Respiratory tract infection | Infections and infestations | Intravenous GLM (IV-GLM) 2 mg/kg + SC GLM 50 mg | 0 | 245 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00975130/events